Highlight
- The ARDS, Pneumonia, and Sepsis (APS) Consortium is a national multicenter initiative designed to characterize critical illness syndromes through biologically-driven phenotyping.
- The APS Consortium Phenotyping Study has successfully enrolled 1,000 critically ill adults ahead of schedule, collecting extensive clinical data and biospecimens.
- High rates of biospecimen collection across multiple biological compartments support the feasibility of deep phenotyping critical illness states.
- Expert adjudication revealed substantial overlap and heterogeneity with 40% classified as ARDS, 52% as pneumonia, and 89% as sepsis, underscoring the need for precision approaches in treatment.
Study Background
Acute respiratory distress syndrome (ARDS), pneumonia, and sepsis represent complex, highly morbid syndromes commonly encountered in critical care settings. These conditions are marked by heterogeneity in clinical presentation, biological pathways, and treatment responses, contributing to suboptimal therapeutic advances despite decades of research. The burden of these illnesses remains substantial, with high mortality rates and long-term morbidity among survivors.
Advancements in precision medicine hold promise for addressing this heterogeneity by subclassifying patients into biologically and pathophysiologically relevant phenotypes. Such phenotyping could enable targeted therapeutic strategies and refined prognostication. However, large-scale, integrated platforms incorporating comprehensive clinical data and biospecimen repositories had been lacking.
Recognizing this need, the National Institutes of Health (NIH) launched the ARDS, Pneumonia, and Sepsis (APS) Consortium to develop a national platform aimed at enabling deep phenotyping across these overlapping syndromes to accelerate biological understanding and therapeutic development.
Study Design
The APS Consortium Phenotyping Study is a longitudinal, multicenter, prospective observational cohort study targeting enrollment of 4,000 critically ill adults diagnosed with ARDS, pneumonia, and/or sepsis over a four-year period. The consortium engages multiple academic sites across the United States.
Eligible participants are adults admitted to intensive care units with clinical diagnoses of one or more of the three syndromes. Data collection encompasses multiple domains including chronic health status, acute clinical illness characteristics, and long-term recovery metrics. Biospecimen collection is comprehensive, involving blood, upper and lower respiratory tract samples, urine, and gastrointestinal specimens.
A key aim is to generate richly phenotyped patient subsets by integrating clinical, molecular, and microbiologic data to identify biologically coherent patient groups within these syndromes. Expert adjudication panels review clinical data to confirm diagnoses alongside standard criteria.
Key Findings
As of the initial feasibility assessment, the study enrolled its first 1,000 participants within 13 months—significantly ahead of planned recruitment schedules—demonstrating the feasibility of rapid data and specimen collection in critically ill populations.
The enrolled cohort had a median age of 64 years, underscoring the vulnerability of older adults. Clinical severity was high: 75% required vasopressor support, half underwent invasive mechanical ventilation, and a quarter died within four weeks of enrollment, consistent with mortality rates reported for severe ARDS, sepsis, and pneumonia.
Biospecimen collection rates were excellent, with nearly all participants (>98%) providing blood and upper respiratory samples, and substantial numbers providing urine (80%), gastrointestinal (65%), and lower respiratory tract samples (37%). This breadth of biological material supports multi-omics phenotyping strategies.
Expert adjudication classified 40% of patients as having ARDS, 52% pneumonia, and 89% sepsis; many patients met criteria for multiple syndromes reflecting clinical overlap. This highlights the interconnected pathogeneses and underpins the rationale for integrated phenotypic analysis.
Expert Commentary
The APS Consortium sets a new standard for phenotyping studies in critical illness by demonstrating that coordinated multicenter efforts can deliver timely and quality data and biospecimens at scale. This infrastructure is crucial to overcome past challenges in heterogeneity that have stalled therapeutic innovation.
The inclusion of multiple biospecimen types allows for an integrated systems biology approach, combining immunologic, genomic, microbiologic, and metabolomic data with clinical phenotypes, which is increasingly recognized as essential in dissecting ARDS and sepsis pathophysiology.
Challenges remain, including ensuring longitudinal follow-up and harmonizing phenotyping definitions across sites. However, the early success in recruitment and sample collection is reassuring.
Moreover, the ongoing integration with expert adjudication enhances diagnostic accuracy and facilitates research reproducibility. These features will ultimately enable the validation of molecular phenotypes and biomarkers predictive of clinical outcomes and therapeutic response.
Conclusion
The APS Consortium Phenotyping Study successfully demonstrates the operational feasibility and clinical relevance of establishing a national platform for deep phenotyping of ARDS, pneumonia, and sepsis. Early data indicate that such efforts can yield rich datasets and biospecimens from a severely ill, heterogeneous patient population.
This initiative paves the way for innovative, biology-driven classification of critical illness syndromes, which may transform clinical trial design and patient management in critical care medicine. The full enrollment target of 4,000 participants is projected to provide sufficient power to validate meaningful biological subgroups and accelerate precision medicine approaches.
Funding and Trial Registration
The study is funded through the National Institutes of Health. It is registered on ClinicalTrials.gov under the identifier NCT06521502.
References
- Self WH, Calfee CS, Brown SM, et al. The ARDS, Pneumonia, and Sepsis (APS) Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes. Chest. 2026 Jul 13. PMID: 42442528.
- Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611-620.
- Shankar-Hari M, Harrison DA, Rubenfeld GD, et al. Epidemiology and clinical outcomes of sepsis in critical care units: a systematic review. Intensive Care Med. 2020;46(6):1069-1082.
- Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Med. 2021;47(11):1181-1247.
